News archive
Showing 680 results
April 2020
-
Media Release
Novartis US Foundation supports telehealth programs to provide access to care for New Jersey's most vulnerable communities
-
Media Release
Novartis US Foundation supports telehealth programs to provide access to care for New Jersey's most vulnerable communities
Partnership with NJPCA, which represents 23 community health centers in NJ, funded 5 telehealth pilots; programs serving as role models for centers across state The Grant enabled NJ community… -
Media Release
Novartis and the Novartis US Foundation establish USD 5 million US COVID-19 Community Response Fund
Funding and in-kind donations to support local initiatives and communities in the US impacted by the outbreak First grants to focus on immediate need for digital tools and frontline medical…
March 2020
-
Media Release
Novartis new analysis further shows durable and potent LDL-C reduction with inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment
Prespecified analysis of pooled data from ORION-9, -10 and -11 Phase III clinical trials showed inclisiran reduced low-density lipoprotein-cholesterol (LDL-C) by 51% at 17 months1 Prespecified… -
Media Release
Novartis new analysis further showed durable and potent LDL-C reduction with inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment
- Prespecified analysis of pooled data from ORION-9, -10 and -11 Phase III clinical trials showed inclisiran reduced low-density lipoprotein-cholesterol (LDL-C) by 51% at 17 months(1)- Prespecified… -
Media Release
Novartis new analysis further showed durable and potent LDL-C reduction with inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment
-
Media Release
Novartis new analysis further showed durable and potent LDL-C reduction with inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment
- Prespecified analysis of pooled data from ORION-9, -10 and -11 Phase III clinical trials showed inclisiran reduced low-density lipoprotein-cholesterol (LDL-C) by 51% at 17 months(1)- Prespecified… -
Media Release
Novartis announces NEJM publication of three pivotal trials showing durable and potent efficacy of inclisiran, an investigational first-in-class siRNA cholesterol-lowering therapy
Inclisiran, an investigational medicine, showed durable and potent reduction of low-density lipoprotein cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease (ASCVD), ASCVD… -
Media Release
Novartis Pharmaceuticals Corporation corrective action for certain blister packages of SANDIMMUNE® and NEORAL® 100-mg soft gelatin capsules in the US due to failure to meet child-resistant packaging requirements
Consumer Product Safety Commission-approved corrective action issued after Novartis identified that certain blister card packages of SANDIMMUNE® (cyclosporine capsules, USP) 100-mg soft gelatin…
February 2020
-
Media Release
Novartis announces MET inhibitor capmatinib (INC280), the first potential treatment for METex14 mutated advanced non-small cell lung cancer, granted priority FDA review
- FDA Priority Review for capmatinib based on Phase II data in first-line and previously treated patients with MET exon 14 skipping (METex14) mutated advanced non-small cell lung cancer (NSCLC)(1)-… -
Media Release
Novartis announces MET inhibitor capmatinib (INC280), the first potential treatment for METex14 mutated advanced non-small cell lung cancer, granted priority FDA review